Michèle Ollier
Director/Board Member presso IPSEN
Patrimonio netto: 59 562 $ in data 31/03/2024
Profilo
Michèle Ollier founded Medicxi Ventures (Jersey) Ltd.
in 2015, where she is working as Partner from 2015.
Dr. Ollier also currently works at Kaerus Bioscience France SASU, as Chief Executive Officer, Ipsen SA, as Independent Director from 2015, LinguaFlex, Inc., as Director, Epsilon-3 Bio Ltd, as Director, Palladio Biosciences, Inc., as Director, Mavalon Therapeutics Ltd., as Director from 2016, Human Antibody Factory Ltd., as Director, Kaerus Bioscience Ltd., as Director, Villaris Therapeutics, Inc., as Director, and Medicxi Ventures (Jersey) Ltd.
(Switzerland), as Partner.
Dr. Ollier also formerly worked at Funxional Therapeutics Ltd., as Chairman, Mind-NRG SARL, as Chairman, Aegerion Pharmaceuticals, Inc., as Director from 2007 to 2011, NormOxys, Inc., as Director, Diasome Pharmaceuticals, Inc., as Director, Rhone-Poulenc Rorer, Inc., as Director-International Oncology in 2000, Andera Partners SCA, as Director-Life Sciences Investment in 2006, OncoEthix SA, as Director, Bristol-Myers Squibb SARL, as Group Director-Lipid Lowering Agents from 1989 to 1992, Cyrenaic Pharmaceuticals, Inc., as Director from 2010 to 2014, Profibrix BV, as Director-Supervisory Board, Sonkei Pharmaceuticals, Inc., as Director, Minerva Neurosciences, Inc., as Independent Director from 2014 to 2017, EnCare Biotech BV, as Director, Stx Pharma Ltd., as Director, Gadeta BV, as Director, Kymo Therapeutics Ltd., as Director, Abtco BV, as Director, Sanofi, as Manager-CNS Product in 1989, Serono SA, as Vice President-International Reproductive Health from 2000 to 2002, and Index Ventures SA, as Partner from 2009 to 2016.
Dr. Ollier received her doctorate degree from Université Paris Nanterre.
Partecipazioni note in società pubbliche
Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
---|---|---|---|---|
IPSEN SA
0.00% | 31/12/2022 | 500 ( 0.00% ) | 59 562 $ | 31/03/2024 |
Posizioni attive di Michèle Ollier
Società | Posizione | Inizio |
---|---|---|
IPSEN | Director/Board Member | 27/05/2015 |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Founder | 03/11/2015 |
Villaris Therapeutics, Inc.
Villaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Villaris Therapeutics, Inc. is an asset-centric biopharmaceutical company. The company is based in Cary, NC. The company was founded in 2019 by John Harris. The CEO is Andrea Epperly. | Director/Board Member | - |
Medicxi Ventures (Jersey) Ltd. (Switzerland) | Corporate Officer/Principal | - |
Mavalon Therapeutics Ltd.
Mavalon Therapeutics Ltd. Medical SpecialtiesHealth Technology Mavalon Therapeutics Ltd. develops orally available small molecule able to induce glial cell line-derived neurotropic factor production within the brain of parkinson’s patients. The company is headquartered in Hatfield, the United Kingdom. | Director/Board Member | 22/02/2016 |
Kaerus Bioscience Ltd. | Director/Board Member | - |
Human Antibody Factory Ltd.
Human Antibody Factory Ltd. BiotechnologyHealth Technology Human Antibody Factory Ltd. provides research and experimental development on biotechnology. The company was founded by David John Grainger and is headquartered in Hatfield, the United Kingdom. | Director/Board Member | - |
Palladio Biosciences, Inc.
Palladio Biosciences, Inc. BiotechnologyHealth Technology Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA. | Director/Board Member | - |
LinguaFlex, Inc.
LinguaFlex, Inc. Medical SpecialtiesHealth Technology LinguaFlex, Inc. develops, manufactures and distributes medical devices for the treatment of sleep apnea. It offers the LinguaFlex Tongue Retractor which is a minimally invasive device designed to be inserted into the tongue by a thin needle. The LinguaFlex Tongue Retractor is designed not to interfere with normal tongue functions such as speech and swallowing and to be removed or replaced in a doctor’s office in a short period of time without the need for anesthesia. The company was founded by Ira Sanders in 2007 and is headquartered in Pittsburgh, PA. | Director/Board Member | - |
░░░░░░░░░ ░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Precedenti posizioni note di Michèle Ollier
Società | Posizione | Fine |
---|---|---|
░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░ ░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░░░░░ ░░ | ░░░░░░░ ░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formazione di Michèle Ollier
Université Paris Nanterre | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 3 |
---|---|
SANOFI | Health Technology |
IPSEN | Health Technology |
MINERVA NEUROSCIENCES, INC. | Health Technology |
Aziende private | 29 |
---|---|
Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
NormOxys, Inc.
NormOxys, Inc. Pharmaceuticals: MajorHealth Technology NormOxys, Inc. develops small-molecule therapeutics for the treatment of cancer. Its major product is OXY111A. The company was founded by Conrad J Bletzer, Jr. Claude Nicoalu, Jean-Mearie Lehn, Gay Goodman, Ruth Greferath and Roscoe Brady in 2004 and is headquartered in Brighton, MA. | Health Technology |
Diasome Pharmaceuticals, Inc.
Diasome Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Diasome Pharmaceuticals, Inc. operates as a clinical stage diabetes therapeutics company which designs and develops insulin-based therapies for the treatment of diabetes. It focuses on the clinical and commercial development of breakthrough therapies for diabetes and obesity. The company’s technology platform is based on the use of its proprietary Hepatocyte Directed Vesicle or HDV, nanotechnology to deliver a wide range of critically necessary hormones and drugs to the liver, the body’s primary site of glucose storage. The firm’s HDV system is designed to fundamentally improve the way in which insulin works in people with diabetes by enabling much greater amounts of injected insulin to reach hepatocytes, the liver’s glucose storing cells. The company was founded by Len Rosenberg, Lance Converse, W. Blair Geho and Robert Geho in 2004 and is headquartered in Cleveland, OH. | Health Technology |
Serono SA
Serono SA Pharmaceuticals: MajorHealth Technology Serono SA develops products to fight debilitating diseases and other pharmaceutical products. The company has eight biotechnology products on the market and a strong pipeline based on both proteins and small molecules. It's four main Therapeutics Areas are: Reproductive Health, Multiple Sclerosis, Growth & Metabolism, and Dermatology. It focuses on recombinant genetic engineering to develop drugs. The firm also focuses on neurological, metabolic, and human growth disorders. Other products include treatments for growth hormone deficiency, and AIDS-related wasting. The company is headquarterd in Geneva, Switzerland. | Health Technology |
Index Ventures SA
Index Ventures SA Investment ManagersFinance Index Ventures SA (Index Ventures) is a venture capital firm founded in 1996 by Neil Alexander Rimer, Gluseppe Zocco and Gerald Rimer. The firm is headquartered in Geneva, Switzerland. | Finance |
Rhone-Poulenc Rorer, Inc.
Rhone-Poulenc Rorer, Inc. Pharmaceuticals: MajorHealth Technology Rhone-Poulenc Rorer, Inc. discovers, develops and markets human pharmaceuticals. It operates in all major markets of the world. The company is headquartered in Collegeville, PA. | Health Technology |
Andera Partners SCA
Andera Partners SCA Investment ManagersFinance Andera Partners SCA (Andera Partners) is a private equity firm founded in 2001 by Pierre-Michel Passy. The firm is headquartered in Paris, France. | Finance |
OncoEthix SA
OncoEthix SA Pharmaceuticals: MajorHealth Technology OncoEthix SA operates as a clinical stage biotechnology company which develops cancer drugs. Its products include OTX008, OTX015, and OTX009. The company was founded by Esteban Cvitkovic, Jeanne Kay Noel, Yves Paternot, and Patrice Herait in March 2007 and is headquartered in Luzern, Switzerland. | Health Technology |
Funxional Therapeutics Ltd.
Funxional Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Funxional Therapeutics Ltd. is a clinical stage pharmaceutical company, which offers drug and therapeutic development programs. It specializes on anti-inflammatory therapies and compounds. The company was founded by David J. Grainger on August 8, 2011 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Bristol-Myers Squibb SARL
Bristol-Myers Squibb SARL Medical DistributorsDistribution Services Bristol-Myers Squibb SARL engages in the research, development, manufacture, and distribution of pharmaceutical products. Its therapeutic areas include immunoscience, immune-oncology, and cardiology. The company is headquartered in Rueil-Malmaison, France. | Distribution Services |
LinguaFlex, Inc.
LinguaFlex, Inc. Medical SpecialtiesHealth Technology LinguaFlex, Inc. develops, manufactures and distributes medical devices for the treatment of sleep apnea. It offers the LinguaFlex Tongue Retractor which is a minimally invasive device designed to be inserted into the tongue by a thin needle. The LinguaFlex Tongue Retractor is designed not to interfere with normal tongue functions such as speech and swallowing and to be removed or replaced in a doctor’s office in a short period of time without the need for anesthesia. The company was founded by Ira Sanders in 2007 and is headquartered in Pittsburgh, PA. | Health Technology |
Cyrenaic Pharmaceuticals, Inc.
Cyrenaic Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cyrenaic Pharmaceuticals, Inc. a private drug development company focused on the treatment of central nervous system (CNS) disorders. It specializes on the development of CYR-101, an antipsychotic in development for the treatment of schizophrenia. The company was founded in 2007 and is headquartered in Princeton, NJ. | Health Technology |
ProFibrix BV
ProFibrix BV BiotechnologyHealth Technology ProFibrix BV develops and markets products for the hemostasis and regenerative medicine markets. Its product in pipeline, ProFibrix, is a hemostatic agent for mild to moderate surgical bleeding. The firm operates through its offices located in Leiden and Seattle. It is a subsidiary of The Medicines Company. The company was founded in 2004 by Jaap Koopman and is headquartered in Leiden, the Netherlands. | Health Technology |
Sonkei Pharmaceuticals, Inc.
Sonkei Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sonkei Pharmaceuticals, Inc. develops compounds for depression and mood disorders. The firm serves the healthcare and pharmaceutical industries. The company is headquartered in Princeton, NJ. | Health Technology |
Mind-NRG SARL
Mind-NRG SARL Medical/Nursing ServicesHealth Services Mind-NRG SARL specializes in research and development programs with focus on the treatment psychiatric and neurologic diseases. The company was founded in 2010 and is headquartered in Geneva, Switzerland. | Health Services |
Epsilon-3 Bio Ltd
Epsilon-3 Bio Ltd Pharmaceuticals: OtherHealth Technology Epsilon-3 Bio Ltd. develops compounds targeting the removal of cellular debris in chronic inflammatory and autoimmune disorders. The company was founded by Martin W. Edwards, Konstantinos Efthymiopoulos, David J. Grainger and Christian De La Tour on June 18, 2010 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
EnCare Biotech BV
EnCare Biotech BV Medical/Nursing ServicesHealth Services EnCare Biotech BV operates as a biopharmaceutical company which develops therapeutic antibody for the prevention of heart failure after acute myocardial infarction. Its product is a novel therapeutic monoclonal antibody against the EDA fragment of fibronectin. The company was founded by Fatih Arslan in 2014 and is headquartered in Utrecht, the Netherlands. | Health Services |
Stx Pharma Ltd. | |
Medicxi Ventures (Jersey) Ltd.
Medicxi Ventures (Jersey) Ltd. Investment ManagersFinance Medicxi Ventures (Jersey) Ltd. (Medicxi) is an independent venture capital firm founded in 2016 by Francesco de Rubertis, Michèle Ollier, and Kevin S. Johnson. The firm is headquartered in London. | Finance |
Gadeta BV
Gadeta BV Medical SpecialtiesHealth Technology Gadeta BV discovers and develops novel cancer immunotherapies. It provides groundbreaking discoveries regarding the role of cell receptors in the broad of heamatological and solid tumor cells. The firm develops t-cells engineered to express a defined gamma delta, an anti- cancer product that eradicates tumors. The company was founded by Jurgen Kuball in 2015 and is headquartered in Utrecht, Netherlands. | Health Technology |
Kymo Therapeutics Ltd.
Kymo Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kymo Therapeutics Ltd. develops and commercializes therapeutic products . The company was founded on May 23, 2016 and is headquartered in Hatfield, the United Kingdom. | Health Technology |
Palladio Biosciences, Inc.
Palladio Biosciences, Inc. BiotechnologyHealth Technology Palladio Biosciences, Inc. develops transformative medicines for orphan diseases. Its pipeline includes Lixivaptan, a selective vasopressin V2 receptor antagonist for the treatment of polycystic kidney disease, a life-threatening genetic disease. The company was founded by Lorenzo Pellegrini in 2015 and is headquartered in Newtown, PA. | Health Technology |
Abtco BV
Abtco BV Packaged SoftwareTechnology Services Abtco BV offers platform to develop receptors for T cell engineering in oncology with advantages on efficacy and intellectual property position. The company is headquartered in Utrecht, the Netherlands. | Technology Services |
Mavalon Therapeutics Ltd.
Mavalon Therapeutics Ltd. Medical SpecialtiesHealth Technology Mavalon Therapeutics Ltd. develops orally available small molecule able to induce glial cell line-derived neurotropic factor production within the brain of parkinson’s patients. The company is headquartered in Hatfield, the United Kingdom. | Health Technology |
Kaerus Bioscience France SASU
Kaerus Bioscience France SASU Miscellaneous Commercial ServicesCommercial Services Kaerus Bioscience France SASU engages in research and development in biotechnology. The company was founded on February 23, 2017 and is headquartered in Orléans, France. | Commercial Services |
Human Antibody Factory Ltd.
Human Antibody Factory Ltd. BiotechnologyHealth Technology Human Antibody Factory Ltd. provides research and experimental development on biotechnology. The company was founded by David John Grainger and is headquartered in Hatfield, the United Kingdom. | Health Technology |
Kaerus Bioscience Ltd. | |
Villaris Therapeutics, Inc.
Villaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Villaris Therapeutics, Inc. is an asset-centric biopharmaceutical company. The company is based in Cary, NC. The company was founded in 2019 by John Harris. The CEO is Andrea Epperly. | Health Technology |
Medicxi Ventures (Jersey) Ltd. (Switzerland) |
- Borsa valori
- Insiders
- Michèle Ollier